MADISON, Wis.--(BUSINESS WIRE)--The Waisman Clinical Biomanufacturing Facility (WCBF) at the University of Wisconsin-Madison, and Nature Technology Corporation (NTC) of Lincoln, Nebraska, today announced the implementation, at WCBF, of a high-yielding process for clinical manufacturing DNA vaccines and gene-based therapeutics. The process is scalable, from the laboratory bench to clinical trials and final product manufacturing.
